Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis 3. Neuroscience: $5,993M in FY2025, up 26.2% from a year earlier.
Latest, FY2025
5,993
Period ended Dec 31, 2025
Change on a year earlier
+26.2%
4,750 in FY2024
History
4 years
Since FY2022
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Total neuroscience | 5 993 | 4 750 | 26 | 25”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K (Net sales by therapeutic area) & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | 3. Neuroscience ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5,993 | +26.2% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 4,750 | +30.1% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 3,651 | +20.2% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 3,038 | – | Novartis Form 6-K (0001370368-24-000007) ↗ |
Breakdown
What makes up 3. Neuroscience
- Therapeutic Area Revenue Growth at Constant Currencies (% cc)25.0% · FY2025
- Therapeutic Area Revenue Growth in USD (% USD)26.0% · FY2025
- Kesimpta (ofatumumab — self-administered B-cell antibody therapy for relapsing multiple sclerosis RMS)4,426 · FY2025
- Zolgensma Group (onasemnogene abeparvovec — gene therapy for spinal muscular atrophy SMA)1,232 · FY2025
- Aimovig (erenumab — migraine prevention Migraine)335 · FY2025
Cite this data
StockData. (2026). Novartis 3. Neuroscience ($M), annual FY2022–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/ta-neuroscience
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.